Drug Trial Radar · NCT06959108
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
106
Planned (sponsor's estimate)
Start
Oct 13, 2025
Primary completion
Jun 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Lepu Medical Technology (Beijing) Co., Ltd.
- First posted
- May 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the objective response rate (ORR) of patients with LA-HNSCC, treated with induction of EGFR-ADC MRG003 and anti PD-1 Pucotenlimab versus EGFR-ADC MRG003 alone before chemoradiotherapy. People eligible to participate in this study must be between the ages of 18 and 75 and have locally advanced squamous cell carcinoma of the head and neck requiring treatment with chemoradiotherapy (cisplatin combined with radiotherapy). Half of the research participants will receive MRG003 alone as induction before radiochemotherapy and the other half will receive MRG003 combined with pucotenlimab as induction before radiochemotherapy, then pucotenlimab as adjuvant\* after radiochemotherapy.
Conditions
- Locally Advanced Head and Neck Squamous Cell Carcinoma
Interventions
PucotenlimabDrug
200mg every 3 weeks (21-day cycles) for a total of 3 cycles.
MRG003Drug
2.3 mg/kg, every 3 weeks (21-day cycles) for a total of 3 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- objective response rateTime frame: around 20 months after the inclusion of the 1st patient
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.